Skip to content
All resources

Thymosin Alpha-1

Thymosin alpha 1 and Zadaxin: where thymalfasin is approved, and what the trials found

EW

By

· 11 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. The molecule and the name
  2. Where Zadaxin is approved, and for what
  3. The hepatitis B trials
  4. The hepatitis C trials
  5. The COVID-19 studies
  6. Why it is not authorised in Canada
  7. Frequently asked questions

Zadaxin is the brand name of thymalfasin, a synthetic copy of the 28-residue thymic peptide thymosin alpha 1. It is licensed in more than 35 countries, chiefly for chronic hepatitis B and in some for hepatitis C or as a vaccine adjuvant, with its first approval in China. Its hepatitis trials disagree with each other, a 2026 Cochrane review rated most of the evidence very low certainty, and COVID-era studies pointed in both directions. It is not approved by the FDA, and no Canadian authorisation was found.

A thymus gland surrounded by T-cells, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: the thymus, the gland thymosin alpha-1 was first isolated from.

The molecule and the name

Thymosin alpha 1 was isolated and sequenced from calf thymus by Allan Goldstein and colleagues in 1977 (PMID 265536). It is 28 amino acids long with an acetylated N-terminus. Thymalfasin is the international non-proprietary name for the synthetic peptide, and Zadaxin is the brand under which SciClone Pharmaceuticals licensed and marketed it.

That gives three names for one sequence, and a fourth source of confusion: thymosin beta-4, which shares nothing with it but a naming convention, as TB-500 vs thymosin beta-4 explains from the other side. Thymosin alpha-1: what the literature examines covers the mechanism, the Toll-like receptor work and the difference from thymosin beta-4. This page is about the medicine: where it is licensed, on what evidence, and why that licence does not reach Canada.

Where Zadaxin is approved, and for what

Goldstein, reviewing the clinical record in 2009, described thymosin alpha 1 as approved in over 35 countries for the treatment of hepatitis B and C and as an immune stimulant and vaccine adjuvant (PMID 19392576). The approvals are concentrated in Asia, Latin America and the Middle East, and their scope differs by country.

IndicationWhere the record places it
Chronic hepatitis BThe core indication. SciClone's first approval was in China in the mid-1990s, and its 1998 announcements listed hepatitis B approvals in countries including China, Singapore and the Philippines
Chronic hepatitis CApproved in a smaller number of countries, historically alongside interferon
Vaccine adjuvantSciClone's 1998 announcements listed approval as an influenza vaccine adjuvant in Argentina, Italy and Mexico
United StatesNot approved by the FDA for any indication
CanadaNo Canadian marketing authorisation found

The country-by-country list moves over time and is not maintained in any single public source that we could find. What can be said with confidence is the shape: a licensed medicine in a substantial number of countries, built mainly on hepatitis B, with neither the FDA nor Health Canada among them.

The hepatitis B trials

The hepatitis B literature is where Zadaxin's case was made, and it is a literature with a split in it.

The positive trial most often cited. Chien and colleagues in Taiwan randomised 98 patients with biopsy-proven chronic hepatitis B to a 26-week course of thymosin alpha 1, a 52-week course, or no treatment (PMID 9581695). At 18 months, complete virological response — clearance of HBV DNA and HBeAg — was 40.6% in the 26-week group against 9.4% in untreated controls. Two details matter. At the end of treatment, response rates in the three groups were similar; the difference emerged during follow-up. And the longer course did not do better than the shorter one: 26.5%, not significantly different from control. The control group received no placebo, so the trial was not blinded at the level of the intervention, though histology was assessed blind.

The trial that did not confirm it. Mutchnick and colleagues ran a multicentre, randomised, double-blind, placebo-controlled phase 3 study in the United States in 97 patients with HBV DNA- and HBeAg-positive chronic hepatitis B (PMID 10607256). Complete response at 12 months was 14% with thymosin alpha 1, and sustained loss of HBV DNA with negative HBeAg was 25% against 13% with placebo, a difference that was not statistically significant. The authors concluded that their results "do not confirm observations of treatment efficacy reported in other clinical studies."

The systematic review. In September 2026, Naing and colleagues published a Cochrane review of thymosin alpha 1 in chronic hepatitis B: ten randomised trials published between 1991 and 2018, in Bangladesh, China, Italy, Korea, Singapore and Taiwan, with 1,349 participants (PMID 42713852). Pooled estimates favoured thymosin alpha 1 for all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96, three trials) and for serious adverse events. But the certainty was rated very low for every outcome except serious adverse events, which was low, because of risk of bias, imprecision and inconsistency. The reviewers' conclusion was that they were not sure whether thymosin alpha 1 reduces mortality or serious adverse events, and that its effect on hepatitis B-related morbidity is very uncertain. They identified no ongoing trials.

That is the current state of the core indication: a licensed use in many countries, a positive open-label trial, a null placebo-controlled trial in the United States, and a Cochrane review that cannot say with confidence whether it works.

The hepatitis C trials

Before direct-acting antivirals, interferon was the backbone of hepatitis C treatment and response rates were low. Thymosin alpha 1 was tested as an add-on.

Sherman and colleagues randomised 109 patients with biopsy-confirmed chronic hepatitis C to thymosin alpha 1 plus interferon, interferon plus placebo, or placebo for both, double-blind (PMID 9537454). End-of-treatment biochemical response was 37.1% with the combination, 16.2% with interferon alone and 2.7% with placebo. HCV RNA clearance at the end of treatment was 37.1% and 18.9%. The figure that matters most in hepatitis C, sustained response after treatment stopped, was 14.2% against 8.1% — a much smaller gap. The authors described "evidence of biological activity" and called for longer studies.

Goldstein's 2009 review noted late-stage testing in the United States and Europe for hepatitis C at that time (PMID 19392576). Direct-acting antivirals then transformed hepatitis C treatment, and the case for an immune-modulating add-on to interferon largely disappeared with it.

The COVID-19 studies

Thymosin alpha 1 was widely used in China in the first months of the pandemic, which produced a fast, mostly observational literature with conflicting results.

A cohort pointing the wrong way. Liu and colleagues studied 2,282 patients across five hospitals in Hubei between December 2019 and March 2020 (PMID 34408744). After adjustment for confounders, thymosin alpha 1 use was associated with a higher rate of non-recovery (odds ratio 1.5), particularly in more severe disease and with later initiation. A retrospective cohort cannot separate the drug from the reasons it was given, and sicker patients may have been more likely to receive it, but the result is the opposite of the claims made for it.

Two meta-analyses that disagree. Shang and colleagues pooled nine studies with 5,352 patients and found no significant effect on mortality (risk ratio 1.03), concluding that their results "do not support the use" of thymosin alpha 1 in hospitalised adults (PMID 36527881). Soeroto and colleagues pooled eight studies and reported lower mortality in moderate to critical disease (risk ratio 0.59), with heterogeneity of 84% and the effect influenced by sample size, and called for randomised trials (PMID 37845598). Liu and colleagues, in a separate letter, reported that thymosin alpha 1 use was not associated with reduced COVID-19 mortality (PMID 33896653).

The randomised trials that were registered. A US pilot trial of thymalfasin in hospitalised COVID-19 patients with low lymphocyte counts (NCT04487444) was terminated for slow enrolment. A pilot trial in renal dialysis patients (NCT04428008) asked whether it could prevent infection and is listed as completed.

The pattern is familiar from sepsis, where the largest placebo-controlled trial, TESTS, found no clear effect on 28-day mortality after smaller studies had looked encouraging — covered in what is thymosin alpha-1. Observational signals in immune-modulator studies have a poor record of surviving randomisation.

Why it is not authorised in Canada

Health Canada authorises a drug when a manufacturer files a submission and the evidence meets the standard for the indication sought. Authorisation in China, Italy or anywhere else does not carry over. No Canadian marketing authorisation for thymalfasin was found, and no published Health Canada decision on it either, so the reason is not a matter of public record: it may simply never have been submitted here.

What can be said is what any Canadian or US reviewer would face. The US placebo-controlled hepatitis B trial did not confirm efficacy. The hepatitis C signal came before antiviral therapy made the question moot. The largest sepsis trial was null. The Cochrane review rates the hepatitis B evidence as very low certainty. That is not a record that obviously clears a Western registration standard, which is consistent with its absence from both the US and Canadian markets.

Health Canada's Drug Product Database at health-products.canada.ca is the authoritative check, and authorised products in Canada carry an eight-digit Drug Identification Number. Research-grade thymosin alpha 1 is not Zadaxin, carries no such number, and is sold here for laboratory use only. For the framework behind that distinction, see peptides and Canadian law; for how to weigh a licence granted elsewhere against the trials beneath it, see how to read a peptide study.

Supplied here for laboratory use: Thymosin Alpha-1. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What is Zadaxin? Zadaxin is the brand name of thymalfasin, a synthetic version of the 28-amino-acid thymic peptide thymosin alpha 1, marketed by SciClone Pharmaceuticals. It is licensed in more than 35 countries, mainly for chronic hepatitis B, with some approvals for hepatitis C and as a vaccine adjuvant. It is not approved by the FDA and no Canadian authorisation was found.

Is thymosin alpha 1 effective for hepatitis B? The evidence is split. A Taiwanese trial reported higher virological response at 18 months than no treatment; a US placebo-controlled phase 3 trial did not confirm efficacy. A 2026 Cochrane review of ten trials rated most outcomes very low certainty and concluded it is not sure whether thymosin alpha 1 helps.

Was thymosin alpha 1 used for COVID-19? Yes, widely in China early in the pandemic. One large Hubei cohort associated it with worse recovery after adjustment; one meta-analysis found no mortality effect and another reported lower mortality with very high heterogeneity. A US randomised pilot was terminated for slow enrolment. No large randomised trial established a benefit.

Why is Zadaxin approved in some countries but not Canada? Authorisation depends on a manufacturer applying in each country and meeting that regulator's standard. No Canadian submission or decision on thymalfasin was found. Its evidence base, including a null US placebo-controlled trial and very low-certainty systematic review findings, has not produced FDA approval either.

Is research thymosin alpha 1 the same as Zadaxin? It is the same sequence, not the same product. Zadaxin is a manufactured medicine licensed for named indications in specific countries. Research-grade material is a laboratory chemical with no licence, no indication and no Drug Identification Number, sold here for laboratory research only.

Selected Research References

  1. Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences of the USA. 1977;74(2):725-729. pubmed.ncbi.nlm.nih.gov/265536
  2. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion on Biological Therapy. 2009;9(5):593-608. pubmed.ncbi.nlm.nih.gov/19392576
  3. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 1998;27(5):1383-1387. pubmed.ncbi.nlm.nih.gov/9581695
  4. Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis. 1999;6(5):397-403. pubmed.ncbi.nlm.nih.gov/10607256
  5. Naing C, Ni H, Aung HH, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database of Systematic Reviews. 2026;9:CD014610. pubmed.ncbi.nlm.nih.gov/42713852
  6. Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology. 1998;27(4):1128-1135. pubmed.ncbi.nlm.nih.gov/9537454
  7. Liu J, Shen Y, Wen Z, et al. Efficacy of thymosin alpha 1 in the treatment of COVID-19: a multicenter cohort study. Frontiers in Immunology. 2021;12:673693. pubmed.ncbi.nlm.nih.gov/34408744
  8. Shang W, Zhang B, Ren Y, et al. Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. International Immunopharmacology. 2023;114:109584. pubmed.ncbi.nlm.nih.gov/36527881
  9. Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology. 2023;31(6):3317-3325. pubmed.ncbi.nlm.nih.gov/37845598
  10. Liu T, Liu S, Li T, Zhang J. Thymosin a1 use is not associated with reduced COVID-19 mortality. American Journal of Emergency Medicine. 2022;53:252-253. pubmed.ncbi.nlm.nih.gov/33896653

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.